<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03069014</url>
  </required_header>
  <id_info>
    <org_study_id>NSC15001</org_study_id>
    <secondary_id>2015-005263-16</secondary_id>
    <secondary_id>1R01AG051596-01A1</secondary_id>
    <nct_id>NCT03069014</nct_id>
  </id_info>
  <brief_title>Study of LM11A-31-BHS in Mild-moderate AD Patients</brief_title>
  <official_title>A 6-months Prospective, Multi-center, Double-blind, Placebo-controlled, Randomized, Adaptive-trial-design Study to Evaluate Safety, Tolerability and Exploratory Endpoints of Either Placebo or Two Different Oral Doses of LM11A-31-BHS in Patients With Mild to Moderate Probable Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmatrophiX Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>PharmatrophiX Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of 2 doses of LM11A-31-BHS in 180
      patients with Alzheimer's Disease versus placebo and to access biomarker and clinical
      exploratory endpoints of LM11A-31-BHS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this AD Pilot is to conduct a prospective, double-blind, multicenter, phase IIa
      exploratory safety, feasibility and proof-of-concept trial in mild to moderate Alzheimer's
      disease patients with the orally bioavailable p75 neurotrophin receptor ligand LM11A-31-BHS
      dosed twice daily for 26 weeks. Successful completion of this trial will provide the safety,
      endpoint and statistical basis for the design and execution of a phase 2b/3 efficacy trial.
      It will also bring to the AD field a much-needed new set of target mechanisms and will help
      pioneer the strategy of the concomitant targeting of multiple fundamental AD-related
      pathological processes.

      During the 26 weeks study period the eligible patients will be invited to 5 visits.

      Safety monitoring will include the full extent of phase 2 clinical, electrophysiological and
      laboratory testing.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of AEs/SAEs within the 26-week study period</measure>
    <time_frame>26 weeks</time_frame>
    <description>number of subjects with AEs/SAEs, changes in vital signs and laboratory examinations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Statistically relevant changes in CSF-Biomarkers between baseline and final visit</measure>
    <time_frame>26 weeks</time_frame>
    <description>CSF-Biomarkers (tau, ptau, Aβ40, Aβ42, AchE activity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically relevant changes in working memory ability between baseline and final visit assessed with the Controlled Oral Word Association Test (COWAT)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Controlled Oral Word Association Test (COWAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically relevant changes in word fluency between baseline and final visit assessed with the Category Fluency Test (CFT)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Category Fluency Test (CFT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically relevant changes in processing speed between baseline and final visit assessed with the Coding Test (Subtest of the Wechsler Adult Intelligence Scale)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Coding Test (Subtest of the Wechsler Adult Intelligence Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Statistically relevant changes in executive functions between baseline and final visit assessed with the Digit Span test (Subtest of the Wechsler Adult Intelligence Scale)</measure>
    <time_frame>26 weeks</time_frame>
    <description>Digit Span test (Subtest of the Wechsler Adult Intelligence Scale)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">242</enrollment>
  <condition>Mild to Moderate Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>400mg LM11A-31-BHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg LM11A-31-BHS and 400mg Placebo per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800mg LM11A-31-BHS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>800mg LM11A-31-BHS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebos</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>800mg (microcrystalline cellulose with 0.5 - 1% magnesium stearate) per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400mg LM11A-31-BHS</intervention_name>
    <description>1 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning &amp; evening) for 26 weeks</description>
    <arm_group_label>400mg LM11A-31-BHS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>800mg LM11A-31-BHS</intervention_name>
    <description>2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning &amp; evening) for 26 weeks</description>
    <arm_group_label>800mg LM11A-31-BHS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>2 Oral Capsules (200mg of Placebo) twice daily (morning &amp; evening) for 26 weeks</description>
    <arm_group_label>400mg LM11A-31-BHS</arm_group_label>
    <arm_group_label>Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women (non-childbearing potential) with a diagnosis of Alzheimer's disease
             according to McKhann (2011) criteria

          2. Age 50-85 years (50-80 in Czech Republic)

          3. MRI or CT assessment within six months before baseline, corroborating the clinical
             diagnosis of AD and excluding other potential causes of dementia, especially
             cerebrovascular lesions (see exclusion criteria, number 3)

          4. CSF AD specific biomarker profile; positive, defined as CSF Aβ42 &lt; 550 ng l−1 or an Aβ
             40/42 ratio &lt; 0.89

          5. Mild to moderate stage of Alzheimer's disease according to MMSE ≥ 18 and ≤ 26

          6. Absence of major depressive disease according to GDS of &lt; 5

          7. Modified Hachinski Ischemic Scale ≤ 4

          8. Formal education for eight or more years

          9. Previous decline in cognition for more than six months as documented in patient
             medical records

         10. A caregiver available and living in the same household or interacting with the patient
             a sufficient time each week (in Czech Republic: providing personal care for the
             patient during at least 10 hours per week ) and available if necessary to assure
             administration of drug

         11. Patients living at home or nursing home setting without continuous nursing care

         12. General health status acceptable for a participation in a 6-month clinical trial

         13. Ability to swallow capsules

         14. Stable pharmacological treatment of any other chronic condition for at least one month
             prior to screening

         15. Stable treatment with one of the acetylcholinesterase inhibitors donepezil (Aricept
             ®), galantamine (Razadyne®), or rivastigmine (Exelon) or the partial NMDA receptor
             antagonist with memantine (Namenda®) at least 3-months before baseline Visit or
             Combination of both treatments mentioned above

         16. No regular intake of prohibited medications as noted in Section 11.8 of the protocol

         17. Signed informed consent by the patient, examined and verified to be mentally capable
             by an independent physician, prior to the initiation of any study specific procedure.
             Signed consent of the caregiver (see inclusion criteria 10).

        Exclusion Criteria:

          1. Failure to perform screening or baseline examinations

          2. Hospitalization or change of chronic concomitant medication one month prior to
             screening or during screening period

          3. Clinical, laboratory or neuro-imaging findings consistent with:

               -  Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal
                  dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down's syndrome, etc.)

               -  Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral
                  sclerosis, etc.)

               -  Cerebrovascular disease (major infarct, one strategic or multiple lacunar
                  infarcts, extensive white matter lesions &gt; one quarter of the total white matter)

               -  Other central nervous system diseases (severe head trauma, tumors, subdural
                  hematoma or other space occupying processes, etc.)

               -  Seizure disorder

               -  Other infectious, metabolic or systemic diseases affecting central nervous system
                  (syphilis, present hypothyroidism, present vitamin B12 or folate deficiency,
                  serum electrolytes out of normal range, juvenile onset diabetes mellitus, etc.)

          4. A current DSM-IV diagnosis of active major depression, schizophrenia or bipolar
             disorder

          5. Clinically significant, advanced or unstable disease that may interfere with primary
             or secondary variable evaluations, and which may bias the assessment of the clinical
             or mental status of the patient or put the patient at special risk, such as:

               -  chronic liver disease, liver function test abnormalities or other signs of
                  hepatic insufficiency (ALT, AST, Gamma GT, alkaline phosphatase &gt; 2.5 ULN)

               -  Respiratory insufficiency

               -  Renal insufficiency (serum creatinine &gt; 2mg/dl) or creatinine clearance ≤ 30
                  mL/min according to Cockcroft-Gault formula). In case of creatinine clearance ≤
                  30mL/min, an alternative verification of the renal function must be completed
                  using Cystatin C analysis. In case of normal level of Cystatin C, the patient can
                  be included

               -  Heart disease (myocardial infarction, unstable angina, heart failure,
                  Cardiomyopathy within six months before screening)

               -  Bradycardia (heart beat &lt; 50/min.) or tachycardia (heart beat &gt; 95/min.)

               -  Hypertension (&gt; 180/95 / Czech Republic &gt;160/95) or hypotension (&lt; 90/60)
                  requiring treatment with more than three drugs

               -  AV block (type II / Mobitz II and type III), congenital long QT syndrome, sinus
                  node dysfunction or prolonged QTcB-interval (males &gt; 450 and females &gt; 470 msec.)

               -  Uncontrolled diabetes defined by HbA1c &gt; 8.5

               -  Malignancies within the last five years except skin malignancies (other than
                  melanoma) or indolent prostate cancer

               -  Metastases

          6. Disability that may prevent the patient from completing all study requirements (e.g.
             blindness, deafness, severe language difficulty, etc.)

          7. Women who are fertile and of childbearing potential

          8. Chronic daily drug intake of ≥ 14 days or expected for ≥ 14 days:

               -  benzodiazepines (except lorazepam ≤ 1mg for sleeping disorders only),
                  neuroleptics or major sedatives

               -  Antiepileptics

               -  Centrally active anti-hypertensive drugs (clonidine, l-methyl DOPA, guanidine,
                  guanfacine, etc.)

               -  Opioid containing analgesics

          9. Nootropic drugs with exception of Ginko Biloba

         10. Suspected or known drug or alcohol abuse, i.e. more than approximately 60 g alcohol
             (approximately 1 liter of beer or 0.5 liter of wine / in Czech Republic: 20 g alcohol
             per day for females (500 ml of beer or 250 ml of wine) and 30g alcohol per day for
             males (approximately 750 ml of beer or 375 ml of wine)) per day indicated by elevated
             MCV significantly above normal value at screening

         11. Suspected or known allergy to any components of the study treatments

         12. Enrollment in another investigational study or intake of investigational drug within
             the previous three months

         13. Any condition, which, in the opinion of the investigator, makes the patient unsuitable
             for inclusion

         14. If patient is in any way dependent on the sponsor or the principal investigator or if
             the patient is accommodated in an establishment on judicial or administrative order
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Windisch, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NeuroScios GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8034</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Hall</name>
      <address>
        <city>Hall in Tirol</city>
        <state>Tirol</state>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles University</name>
      <address>
        <city>Praha</city>
        <state>Hlavni Mesto Praha</state>
        <zip>16000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Clinic of Martin Urbanek</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravsky Kraj</state>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vestra clinics s.r.o</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <state>Kralovehadrecky Kraj</state>
        <zip>51601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NEUROHK s.r.o</name>
      <address>
        <city>Chocen</city>
        <state>Pardubicky Kraj</state>
        <zip>56501</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nordwestkrankenhaus Sanderbusch</name>
      <address>
        <city>Sande</city>
        <state>Friesland</state>
        <zip>26452</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für klinische Forschung</name>
      <address>
        <city>Bad Homburg</city>
        <state>Hesse</state>
        <zip>61348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Nordwest</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Magdeburg, Klinik für Neurologie</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen Anthal</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sächsisches Krankenhaus Arnsdorf</name>
      <address>
        <city>Arnsdorf</city>
        <state>Sachsen</state>
        <zip>01477</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmakologisches Studienzentrum Chemnitz GmbH</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologie Sendlinger Strasse Studien- und Gedächtniszentrum München</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU München Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundació ACE</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación de Gestión Sanitaria del Hospital de la Santa Creu I Sant Pau, C</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University</name>
      <address>
        <city>Stockholm</city>
        <state>Stockholms Iän</state>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 3, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2017</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

